MOG 和 AQP4 自身抗体检测时代的多发性硬化症诊断 - 一项单中心研究。
Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
机构信息
Clinic of Neurology and Neurophysiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
出版信息
J Neurol Sci. 2021 Feb 15;421:117289. doi: 10.1016/j.jns.2020.117289. Epub 2020 Dec 20.
BACKGROUND
Myelin oligodendrocyte glycoprotein-IgG-associated encephalomyelitis (MOG-EM) and neuromyelitis optica spectrum disorders are challenging differential diagnoses of multiple sclerosis (MS). Hence, there is uncertainty, whether to test all MS patients for corresponding antibodies. Our objective was to provide a systematic study on the frequency of MOG and Aquaporin-4 (AQP4) autoantibodies in MS patients to evaluate a possible risk of misclassification.
METHODS
Retrospective study in MS patients (including an unselected cohort of patients diagnosed with MS, a cohort of patients with PPMS and a healthy control group) for seroprevalence of MOG and AQP4 autoantibodies by cell-based assay.
RESULTS
None of 241 patients with relapsing-remitting, 19 with secondary progressive and 82 with primary progressive MS revealed MOG or AQP4 autoantibodies.
CONCLUSION
General testing of MOG and AQP4 autoantibodies in MS patients seems not necessary, but should be limited to selected cases only.
背景
髓鞘少突胶质细胞糖蛋白-IgG 相关脑脊髓炎（MOG-EM）和视神经脊髓炎谱系疾病是多发性硬化症（MS）的具有挑战性的鉴别诊断。因此，对于所有 MS 患者是否都要进行相应抗体检测存在不确定性。我们的目的是对 MS 患者中 MO 和水通道蛋白-4（AQP4）自身抗体的频率进行系统研究，以评估可能的误诊风险。
方法
通过细胞检测对 MS 患者（包括未经选择的 MS 患者队列、继发进展型 MS 患者队列和健康对照组）进行 MO 和 AQP4 自身抗体的血清流行率的回顾性研究。
结果
241 例复发缓解型、19 例继发进展型和 82 例原发进展型 MS 患者均未检出 MO 或 AQP4 自身抗体。
结论
MS 患者一般不需要进行 MO 和 AQP4 自身抗体的常规检测，而应仅限于特定病例。
Zotero 插件